None declared, Tomoya Nishino: None declared, Atsushi Kawakami Grant/ research support from: Astellas Pharma, Consultant for: Astellas Pharma, Speakers bureau: Astellas Pharma.


QUALITATIVE AND QUANTITATIVE ANALYSIS OF THE IMMUNOLOGIC CHARACTERISTICS OF THE MINOR SALIVARY GLAND BIOPSY IN SJÖGREN’S SYNDROME

HYE SANG PARK1, Laura Martinez-Martinez1, Berta Magallares1,2, Ivan Castelvi1, Cesar Diaz-Tome1, Ana Laiz1, Patricia Moya1,2, Ana Milena Millan Arinciegas1, Andrea Garcia-Guillen1, Sycille Jeria1, David Lobo1, Susana P. Fernandez-Sanchez1, Conxita Pitarch2, Manel Riera2, Maria Carmen Hernandez Lafuente1, Cândido Jure2, Hector Comorinas1, HOSPITAL DE LA SANTA CREU I SANT PAU, BARCELONA, Spain; 2HOSPITAL DOS DE MAIG, BARCELONA, Spain

Background: Minor salivary gland biopsy (MSGB) is the most important diagnostic test of Sjögren’s Syndrome (SS). It demonstrates the presence of the inflammatory infiltration in the most affected site. It’s possible role as a biomarker in the disease is still unknown. The Immunology Department of our center conducts a detailed analysis of the MSGB about the leukocyte infiltration and quantifies number of each cell.

Methods: To describe the immunologic features of the MSGB and carry out an association analysis with clinical variables.

Results: In 2017, a total of 104 MSGB were carried out in our center. Among them 58 were diagnosed as SS by medical and ACR/EULAR 2016 criteria. Finally 41 patients with SS and abnormal MSGB result were included for this study.

Basal characteristics of patients

<table>
<thead>
<tr>
<th></th>
<th>Frequency (number/percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>8/19,5%</td>
</tr>
<tr>
<td>Extraglandular disease</td>
<td>9/32,8%</td>
</tr>
<tr>
<td>ESSDAI≥2</td>
<td>17/41,46%</td>
</tr>
<tr>
<td>Other autoimmune diseases</td>
<td>2/4,87%</td>
</tr>
<tr>
<td>Ac, Ro/La</td>
<td>0/0</td>
</tr>
<tr>
<td>CRP</td>
<td>8/19,51%</td>
</tr>
<tr>
<td>ANA pattern</td>
<td>13/31,71%</td>
</tr>
<tr>
<td>Homogenous</td>
<td>16/39,02%</td>
</tr>
<tr>
<td>Speckled</td>
<td>10/24,39%</td>
</tr>
<tr>
<td>Speckled and Homogeneous</td>
<td>6/14,64%</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

Details:

- Biopsy: Patients with active disease (ESSDAI=2) had greater amount of cells (µ 159 cells vs 509 cells; p=0.055) as well as those with extraglandular disease (µ 160 vs 488; p=0.08). Patients with active disease also had larger number of infiltration focus (p=0.062). The presence of isolated CD8+ T cells was observed in 13 patients and they had lesser cells (µ 136 vs 381; p=0.35). In those samples with predominance of T cells over B cells had larger number of infiltrate focus (7/20; 35% vs 12/21; 57.14%; p=0.155).

- Disease evolution time was similar with a mean duration of 8-9 years in both groups.

- Corticosteroids: There were 3 patients with active steroid treatment at the moment of the biopsy. All 3 of them had >1 focus in the sample and 2 of them had large infiltrate with >150 cells. Eight of them had received steroids in the last 5 years, 6 of them had large infiltrate with >150 cells and 4 had >1 infiltrate focus in the biopsy. A study with more sample should be carried out to study the influence of steroids in the biopsy results.

- Conclusion: In 14 patients specific antibodies and antinuclear antibodies were negative. In these patients the biopsy is the most useful diagnostic test. Possible association of those variables that were statistically not significant should not be ruled out due to the small sample size of the study.

Disclosure of Interests: HYE SANG PARK: None declared, LAURA MARTINEZ-MARTINEZ: None declared, Berta Magallares: None declared, Ivan Castelvi Consultant for: I received fees less than 500USD as a consultant for Kem and Actelion, Paid instructor for: I received fees less than 2000USD as a instructor for Boehringer -Ingelheim, Novartis and Gebo, Speakers bureau: ND, Cesar Diaz-Tome: None declared, Ana Laiz Consultant for: Lilly, Novartis, AbbVie, MSD, UCB and Janssen, Speakers bureau: Lilly, Novartis, Abvive, MSD, UCB and Janssen, Patricia Moya: None declared, Ana Milena Millan Arinciegas: None declared, Andrea Garcia-Guillen: None declared, Sycille Jeria: None declared, DAVID LOBO: None declared, Susana P. Fernandez-Sanchez: None declared, CONXITA PITARCH: None declared, MANEL RIERA: None declared, MARIA CARMEN HERNANDEZ LAUFENTE: None declared, Cándido Jure: None declared, Hector Comorinas: None declared


NEW PROSPECTIVE OF COGNITIVE IMPAIRMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A PRAGMATIC LANGUAGE EVALUATION

Carmelo Pirone1, Fulvia Cecarelli1, Concetta Minea2, Alfredo Mascio2, Carlo Percione1, Barbara Mazzotta1, Laura Massaro1, Francesca Spinelli1, Cristiano Alessandri1, Guido Valesini2, Fabrizio Conti1, 1Sapienza Università di Roma, Lupus Clinic, Dipartimento di Medicina Interna e Specialità Mediche, Roma, Italy; 2Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy.

Background: Cognitive impairment (CI) in Systemic Lupus Erythematosus (SLE) is a frequent neuropsychiatric manifestation affecting several domains, even in apparently asymptomatic patients. Current research revealed that the typical CI pattern affects frontal-subcortical circuit and thus executive functions. The impairment of non-literall language or Pragmatic Language (PL), including metaphors, idioms, inferences or irony has been well described in several conditions such as autism disorders, Parkinson’s disease, brain injury and even in earlier phases of neurodegenerative processes. Even if PL neuro-anatomy remains controversial, correlation between executive dysfunctions and non-literal language involvement has been reported both in traumatic injury and mild cognitive impairment patients. Nonetheless, no specific study has been performed to evaluate PL impairment in SLE patients so far.

Objectives: We aimed at assessing the PL domain in a monocentric SLE cohort in comparison to healthy controls, matched to age and education, through a specific battery, BLED [1]. Secondly, we focused attention on possible correlations between CI and clinical and laboratory SLE-related features.

Methods: Forty adult patients affected by SLE, according to the ACR criteria, and thirty healthy subjects were enrolled consecutively in this cross-sectional study. The protocol included complete physical examination, extensive clinical and laboratory data collection (comprehensive of demographics, past medical history, co-morbidities, disease activity, chronic damage evaluation, previous and concomitant treatments) and cognitive assessment for five different domains: memory, attention, pragmatic language, executive and visuospatial functions. Self-reported scale for anxiety and depression were performed to exclude the influence of mood disorders on cognitive dysfunction.

Results: We enrolled forty Caucasian SLE patients (MF 3/37; mean±SD age 45.9±10.1 years, mean±SD disease duration 120.8±81.2 months) and thirty healthy subjects (MF 9/21; mean±SD age 41.3±13 years). According to the low level of disease activity and damage (mean±SD SLEDAI-2K of 1.3±2.3, mean±SD SDI of 0.2±0.5), only 30% of patients was on glucocorticoid treatment at the study entry. PL was the most compromised domain in terms of Mean Domain Z scores (Fig. 1). As regards the Domain Cognitive Dysfunction score, a deficit of PL was observed in 45% of patients and respective PL was less relevant than memory, executive and visuospatial functions impairment (P<0.0002, P=0.0002 and P<0.000001, respectively). According to Global Cognitive Dysfunction score 25% of patients experienced a mild impairment and 7.5% a moderate one. Anti-phospholipid antibodies positivity was significantly associated with memory impairment (P<0.0005), whereas the presence of other neuropsychiatric events was associated with executive dysfunctions (P<0.05); neither further significant association nor correlation were identified.

Disclosure of Interests: HYE SANG PARK: None declared, LAURA MARTINEZ-MARTINEZ: None declared, Berta Magallares: None declared, Ivan Castelvi Consultant for: I received fees less than 500USD as a consultant for Kem and Actelion, Paid instructor for: I received fees less than 2000USD as a instructor for Boehringer -Ingelheim, Novartis and Gebo, Speakers bureau: ND, Cesar Diaz-Tome: None declared, Ana Laiz Consultant for: Lilly, Novartis, AbbVie, MSD, UCB and Janssen, Speakers bureau: Lilly, Novartis, Abvive, MSD, UCB and Janssen, Patricia Moya: None declared, Ana Milena Millan Arinciegas: None declared, Andrea Garcia-Guillen: None declared, Sycille Jeria: None declared, DAVID LOBO: None declared, Susana P. Fernandez-Sanchez: None declared, CONXITA PITARCH: None declared, MANEL RIERA: None declared, MARIA CARMEN HERNANDEZ LAUFENTE: None declared, Cándido Jure: None declared, Hector Comorinas: None declared


THU0275

THU0274
CHARACTERISTICS OF NEUROLOGIC INVOLVEMENT AND ITS RELATED FACTORS IN PRIMARY SJÖGREN SYNDROME

mindi qiu, Yuting Jiang, Wen Yang, Jieuo Gu. The third affiliated Hospital of Sun Yat-sen University, rheumatology, guangzhou, China

Background: Neurological manifestations seem common in primary Sjögren’s syndrome (pSS) but their reported prevalences vary in Chinese. And few studies reveal if the disease activity is associated with neurological involvement.

Objectives: To analyze the clinical neurological manifestations of primary Sjögren syndrome (pSS), and to evaluate the relationship with disease activity.

Methods: 112 patients (76 male, 105 female) who fulfilled the 2002 American-European Consensus Group criteria for pSS were enrolled in the study. For each patient, the clinical features were evaluated by medical data including clinical, laboratory and immunologic data, and neurological examinations including electromyography, magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram. Statistical methods used were t-test, chi-square test and Logistic regression.

Results: Data at inclusion were available for 112 patients, whose mean age was 55±10 years. Neurological involvement was noted in 19.6(22/112) patients, including 17(52.9%) with peripheral nervous system (PNS) manifestations, 3(8.4%) with central nervous system (CNS) manifestations and 2(1.8%) with both PNS and CNS involvements. Optic neuritis and trigeminal neuralgia were revealed frequently in cranial neuropathy. Anti-aquaporin 4 antibody was detected in two patients with optic neuritis. The clinical spectrum of peripheral neuropathies encountered in Sjögren’s syndrome patients was wide with sensory neuropathies being the most common. Tibial nerve, peroneal nerve and sural nerve were the most likely involved. 

Conclusion: Neuropathy is not a rare manifestation of pSS. Prevalence of neurological involvement in pSS is 19.6%. Raynaud phenomenon and high disease activity may be the risk factors for neuropathy. Autoantibodies might contribute to the injury of the nervous system.

REFERENCES:

Disclosure of Interests: Carmelo Pironc: None declared, Fulvia Ceccarelli: None declared, Concetta Mina: None declared, Alfredo Mascolo: None declared. Carlo Perricone Speakers bureau: BMS; Lilly, Celgene, Sanofi, Barbaranz Mattzza: None declared, Laura Massaro: None declared, Francesca Spinnelli: None declared, cristiano alessandrini: None declared, Guido Valesini: None declared, fabrizio conti: None declared.


THU0277 HOW THE AGE AT DIAGNOSIS MODIFIES THE PHENOTYPE OF PRIMARY SJÖGREN SYNDROME: ANALYSIS IN 11,420 PATIENTS (BIG DATA SJÖGREN PROJECT)


Abstract THU0277 – Figure 1. Distribution of neurocognitive impairment expressed in Mean Domain Z score.